MEDIFIRST SOLUTIONS ANNOUNCES SHAREHOLDER UPDATE
September 13 2016 - 11:46AM
InvestorsHub NewsWire
Medifirst continues to ramp up for sales
Freehold, NJ -- September 13, 2016 -- InvestorsHub NewsWire
-- MEDIFIRST SOLUTIONS, INC. (OTCQB:
MFST) (the “Company” or “Medifirst”) would like to update
shareholders regarding recent company developments. As previously
announced, Medifirst Solutions, Inc., received 510(k) clearance
from the U.S. Food and Drug Administration (“FDA”) to market its
infrared Time Machine TTML-8102000 Laser Thermal Therapeutic
Device.
Medifirst is pleased to announce that it has made substantial
progress in setting up its infrastructure for sales and compliance.
The Company has engaged MDI Consultants, a leading provider of
quality assurance, regulatory compliance, FDA consulting and
clinical services to the healthcare industry. MDI Consultants will
be hands-on with assisting and overseeing the implementation of the
Company’s internal controls and procedures as mandated by the FDA.
These controls and procedures will be implemented in the Company’s
sales office, as well as at its manufacturer’s facility. Commented
President Bruce J. Schoengood, “We are very pleased to continue our
relationship with MDI Consultants, who played a crucial role in
successfully getting the FDA clearance, as Medifirst enters into
the sales phase of operations.”
In preparing to ramp up and roll out its sales division, Medifirst
is pleased to announce that it has leased new office space in which
to run its sales and training functions and operations which will
include all FDA mandated internal controls and procedures.
Medifirst’s new office space, located in Marlboro, New Jersey, will
provide professional space for training and testing. It will also
handle all administrative functions for the Laser Division.
The Company previously announced that it was aggressively putting
together a sales & distribution team to offer its Time Machine
Lasers in the US market. Continued CEO Schoengood, “We have come to
terms with an experienced National Sales Director with established
credentials in the medical device industry and upon the completion
of contracts and agreements, the Company will release an official
announcement which is anticipated in the upcoming days.
Additionally, the company has come to terms with additional top
industry advisors and announcements are forthcoming as agreements
are completed.”
Continued CEO Schoengood, “Medifirst has also made substantial
progress for financing, inventory and manufacturing, as well as
marketing and advertising. All components of building a national
brand with national sales are being addressed. We will be releasing
updates on these developments in the upcoming days and weeks. The
Company appreciates the patience of its shareholders and supporters
during this exciting time.”
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket
Notification 510(k) submission for “The Time Machine” Series Laser,
received clearance from the U.S. Food and Drug Administration
(“FDA”) to market its infrared Time Machine TTML-8102000 Laser
Thermal Therapeutic Device. The Time Machine Series Lasers Model
TTML-8102000 - 810/830nm is intended for use in temporary relief of
minor muscle and joint pain, stiffness, minor arthritis pain,
muscle spasm, temporary increase in local blood circulation and
temporary relaxation of muscles by means of topical elevated tissue
temperature from infrared spectral emissions. Due to the
decrease of inflammation, patients have seen immediate aesthetic
improvements as well, such as in scar and incision healing. The
hand-held laser device, with pin-point accuracy, often gives
patients immediate results with no redness, swelling or down-time.
This unique laser device offers medical professionals an affordable
and effective tool to enhance their treatment protocols for their
patients and provide new revenue streams for their practice. The
laser division will be operated out of Medifirst's wholly owned
subsidiary, Medical Lasers Manufacturer. Visit
www.medifirstsolutions.com for more information.
Forward-Looking Statements:
The statements in this press release that relate to the company's
expectations with regard to the future impact on the company's
results from new products in development are forward-looking
statements, and may involve risks and uncertainties, some of which
are beyond our control. Such risks and uncertainties are
described in greater detail in our filings with the U.S. Securities
and Exchange Commission. Since the information in this press
release may contain statements that involve risk and uncertainties
and are subject to change at any time, the company's actual results
may differ materially from expected results. We make no
commitment to disclose any subsequent revisions to forward-looking
statements. This release does not constitute an offer to sell or a
solicitation of offers to buy any securities of any entity.
FOR IMMEDIATE RELEASE
Contact: Investor Relations
Phone: (732) 786-8044
Email:
admin@medifirstsolutions.com
Website: www.medifirstsolutions.com